In addition to injectable preparations such as insulin and insulin analogs, glucagon-like peptide 1and oral hypoglycemic drugs, such as peptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitor, are commonly used to treat diabetes (Chatterjee et al., 2017). This evidence concerns the gene INS and diabetes mellitus.